NAD+ for dogs and cats: benefits, precursors, and evidence
NAD+ for dogs and cats explained: proposed benefits, NAD+ versus NMN and NR, primary evidence, limits, and useful veterinarian questions.
Direct answer: NAD+ is a coenzyme, not a peptide. Researchers study NAD+ biology because it is involved in cellular energy reactions, but that biological role does not establish that an NAD+ infusion, oral precursor, or supplement will improve a dog’s or cat’s energy, mobility, recovery, or lifespan. The exact substance, species, route, and measured outcome all matter.
What potential benefits are pet owners investigating?
Owners may encounter NAD+ products while looking for help with low activity, recovery, metabolic health, cognitive aging, or general “healthy aging.” Those are understandable goals, but they are not interchangeable outcomes and they are not verified pet benefits in the primary sources reviewed here. A change in a dog’s willingness to walk or a cat’s appetite can have many causes that require assessment. This guide helps separate the proposed benefit from what a study actually tested.
Why is NAD+ different from a peptide supplement?
NAD+ means nicotinamide adenine dinucleotide in its oxidized form. It is a small coenzyme used in cellular redox reactions. It should not be described as a peptide, which is a chain of amino acids. It also should not be treated as identical to NADH, the reduced form, or to substances the body can use as precursors.
| Label term | What it identifies | Why the distinction matters |
|---|---|---|
| NAD+ | Oxidized nicotinamide adenine dinucleotide | A study of infused NAD+ does not automatically validate an oral precursor. |
| NADH | The reduced form of the coenzyme | NADH and NAD+ participate in the same redox system, but they are not the same label ingredient. |
| NMN | Nicotinamide mononucleotide, an NAD+ precursor | An NMN trial answers a precursor question, not a direct NAD+ product question. |
| NR | Nicotinamide riboside, another NAD+ precursor | Results should remain attached to the exact precursor, formulation, population, and route studied. |
| Niacin or nicotinamide | Vitamin B3 forms that contribute to NAD metabolism | Participation in the same pathway does not make every ingredient or product equivalent. |
What do the primary studies actually show?
The studies below answer three different questions. One tracked metabolites during an NAD+ infusion in people. One tested oral NMN in people. One investigated NMN in mouse models of diabetes. None was a clinical trial showing improved energy, recovery, mobility, cognition, or longevity in household dogs or cats.
| Primary study | Compound, species, and route | What was measured | What it cannot establish for a pet |
|---|---|---|---|
| Grant et al., 2019 | NAD+; 11 healthy adult men; eight received a six-hour intravenous infusion and three received saline | NAD+ and related metabolites in plasma and urine, plus reported biochemical and tolerability observations | It was not oral, not a dog or cat study, and not a demonstration of better everyday energy or longevity. |
| Pencina et al., 2023 | NMN precursor; 30 adults age 45 or older with overweight or obesity; oral tablets for 28 days, randomized 2:1 against placebo | Circulating NAD-related metabolites, body composition, cardiometabolic measures, strength, fatigability, aerobic capacity, and stair climbing | It tested a precursor in people. The abstract reported no significant between-group difference in strength, fatigability, aerobic capacity, or stair climbing. It does not establish a pet benefit. |
| Yoshino et al., 2011 | NMN precursor; mouse models of diet- and age-associated diabetes | NAD biosynthesis, glucose tolerance, insulin sensitivity, and related metabolic mechanisms | An induced mouse disease model is not a clinical result in a household dog or cat, and NMN is not an NAD+ infusion or a peptide. |
This is a focused comparison, not a systematic review of every NAD-related publication. Within this source set, no companion-animal clinical outcome trial was verified. That is a limitation of the review, not proof that no relevant research exists anywhere.
Does raising an NAD-related measurement prove a dog or cat feels better?
No. A biomarker can show that a substance entered a pathway or changed a laboratory measurement. A benefit claim asks a separate question. For example, “circulating NAD-related metabolites increased” is not the same result as “a senior dog walked farther” or “a cat’s daily function improved.” A useful article or product claim should name both the measurement and the outcome instead of replacing one with the other.
Does an intravenous NAD+ study validate an oral energy supplement?
Not on its own. Route affects exposure, and the oral product may contain NMN, NR, a vitamin B3 form, or a blend rather than NAD+ itself. The Grant study followed a six-hour intravenous infusion in people. It cannot be used as direct evidence that a differently labeled oral product improves a pet’s health.
How can you translate an NAD+ headline before acting on it?
Use five checks before connecting a research headline to a dog or cat:
- Write the exact active substance. NAD+, NADH, NMN, NR, and niacin are not interchangeable names.
- Record the route and formulation. An infusion, tablet, diet admixture, and multicomponent supplement answer different questions.
- Name the population. Healthy adults, people with overweight, laboratory mice, dogs, and cats are distinct evidence groups.
- Write the measured endpoint. Separate blood metabolites, glucose tolerance, strength, activity, symptoms, and lifespan.
- Compare that endpoint with the proposed pet benefit. If the study did not measure the claimed outcome in the relevant species, leave that connection unproven.
Worked example: “NMN increased NAD-related metabolites in adults” accurately describes a precursor biomarker result. Rewriting it as “NAD+ restores energy in senior dogs” changes the compound, species, population, and outcome. Those missing links cannot be supplied by the headline.
What should dog and cat owners ask a veterinarian?
- What common medical, medication, nutrition, pain, sleep, or behavior explanations should be considered for this change in activity or function?
- Is the proposed product NAD+ itself, NADH, NMN, NR, a vitamin B3 form, or a blend?
- Does the cited research use the same compound, formulation, route, species, and outcome?
- Could the complete formula interact with the animal’s medicines, supplements, diet, or health conditions?
- What observable outcome and follow-up plan would make the decision assessable rather than based on a vague “energy” promise?
Bring the current label and the animal’s medicines and supplements. Use the printable product and evidence checklist to record exact ingredients, sources, and unanswered questions. A price-per-milligram comparison across NAD+, precursors, and peptides would conceal rather than solve the identity problem.
Frequently asked questions
What are the benefits of NAD+ for dogs or cats?
NAD+ has an essential biological role in cells, but that does not establish a benefit from adding an NAD+ product. The primary sources reviewed here do not demonstrate improved energy, recovery, mobility, cognition, or lifespan in household dogs or cats.
Is NAD+ a peptide?
No. NAD+ is a coenzyme. It is included in this library as a related-compound topic so readers can recognize the category difference and avoid treating every product marketed alongside peptides as a peptide.
Are NMN and NR the same as NAD+?
No. NMN and NR are precursors used in NAD metabolism. Research on one precursor should not be attributed to NAD+ itself or to another precursor without matching evidence.
Does this guide recommend NAD+ for my pet?
No. It explains the evidence question and its limits so you can discuss a specific concern with a veterinarian. A compound’s inclusion in the library is not a product recommendation, and no affiliate offer is attached to this guide.
Can I use a calculator to choose an amount?
The amount-to-volume calculator performs arithmetic using an amount already provided by a veterinarian and a confirmed concentration. It does not select a dose, frequency, route, or product. The concentration calculator likewise uses confirmed final volume; it does not supply mixing instructions.
How should I compare another metabolism-related compound?
Start with the MOTS-c evidence guide, then compare exact identity, species, route, and measured outcome. A shared marketing category is not evidence of equivalence. Use the main peptide guide and topic directory to navigate the full collection.
Prepared by Pet Peptide Guide using the primary sources identified here, checked September 20, 2026. This is AI-assisted editorial research, not veterinary review, product testing, or a clinical protocol. Missing evidence is described as a limit of this focused review, not proof that no research exists. Individual authorship is not invented; the site’s editorial attribution remains transparent.
Sources and scope
This is an introductory guide or original comparison framework, not a systematic review or a product recommendation.
- Grant et al.: NAD+ metabolome during a six-hour intravenous infusion — Eleven healthy adult men, including eight receiving NAD+ and three saline controls; tracked plasma and urine metabolites, not a dog or cat clinical benefit.
- Pencina et al.: oral NMN pilot trial in adults — Thirty adults randomized 2:1 to NMN or placebo for 28 days; tested a precursor in humans, not NAD+ in companion animals.
- Yoshino et al.: NMN in mouse models of diabetes — Metabolic and glucose-related findings in induced mouse models; does not establish an NAD+ product benefit for household dogs or cats.
Source checked September 20, 2026. A general context source does not establish a named product’s benefit.